|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-1.01/-0.60
|
企业价值
175.75M
|
资产负债 |
每股账面净值
1.88
|
现金流量 |
现金流量率
--
|
损益表 |
收益
23.35M
|
每股收益
1.64
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/01/21 08:38 EST
同行比较之报价最少15分钟延迟
业务概览
|
|||
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment. |